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The small leucine-rich proteoglycans (SLRPs) are important regulators of extracellular matrix assembly and
cell signalling. We have determined crystal structures at ~2.2 Å resolution of human fibromodulin and
chondroadherin, two collagen-binding SLRPs. Their overall fold is similar to that of the prototypical SLRP,
decorin, but unlike decorin neither fibromodulin nor chondroadherin forms a stable dimer. A previously identified
binding site for integrin α2β1 maps to an α-helix in the C-terminal cap region of chondroadherin. Interrogation of
the Collagen Toolkits revealed a unique binding site for chondroadherin in collagen II, and no binding to collagen
III. A triple-helical peptide containing the sequence GAOGPSGFQGLOGPOGPO (O is hydroxyproline) forms a
stable complex with chondroadherin in solution. In fibrillar collagen I and II, this sequence is aligned with the
collagen cross-linking site KGHR, suggesting a role for chondroadherin in cross-linking.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The small leucine-rich proteoglycans (SLRPs) consti-
tute a family of secreted proteins with important roles in
extracellular matrix assembly [1,2] and cell signalling [3].
SLRPs are divided into five classes based on sequence
homology. Despite their name, not all SLRPs are
modified with glycosaminoglycan chains, and several of
them are additionally modified by tyrosine sulphation
[1,2]. The biological functions of SLRPs have been
studied in knockout mice and the findings so far suggest
tissue-specific functions of each SLRP, conveyed
through defined temporospatial expression patterns and
interactions with collagen. The data also point to
differential roles of SLRPs in organising collagens into
tissue-specific supramolecular structures [1,2].
Fibromodulin, a class II SLRP, is associated with
dense collagen matrix in tendons and ligaments, as
well as in fibrotic tissues, tumors and atherosclerotic
plaques [4–6]. In fibromodulin-deficient mouse ten-uthors. Published by Elsevier B.V. This is a
rg/licenses/by/4.0/).dons, collagen fibrillogenesis is dysregulated: collagen
fibrils are misassembled [7], collagen α chains are
aberrantly cross-linked, and collagen C-telopeptides
are excessively oxidised by the collagen cross-linking
enzyme, lysyl oxidase [8]. A possible mechanism for
fibromodulin's role in collagen fibrillogenesis is its
recruitment to collagen cross-linking sites and also its
interaction with, and apparent effect on, lysyl oxidase
[9].
One of themore distant homologues of fibromodulin
is chondroadherin, a class IV SLRP found in cartilage
and bone [10]. Chondroadherin-deficient mice have
thinner cortical bones and longer growth plate
proliferation zones [11], as well as mechanically softer
knee surface cartilage [12]. Chondroadherin interacts
with collagen II [13], and mediates cell-matrix interac-
tions through binding to integrin α2β1 [14] and
heparan sulphate [15].
The SLRPs belong to the large superfamily of
leucine-rich repeat (LRR) proteins [16,17], whichn open access article under the CC BY license
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Table 1. Crystallographic statistics.
Fibromodulin Chondroadherin
Data collection
Beamline I04-1 I24
Wavelength (Å) 0.9282 1.739
R e s o l u t i o n
range (Å)
65.9–2.21 (2.27–2.21) 58.4–2.17 (2.23–2.17)
Space group C2 C2
U n i t c e l l
dimensions
a, b, c (Å) 108.11, 98.93, 111.34 215.45, 60.70, 57.66
α, β, γ (°) 90, 107.39, 90 90, 100.60, 90
U n i q u e
reflections
55,434 37,325
Multiplicity 6.8 (6.9) 5.8 (3.9)
Completeness
(%)
99.0 (99.1) 95.8 (75.3)
Mean I/σ(I) 9.5 (1.1) 9.3 (1.6)
CC1/2 0.998 (0.523) 0.987 (0.506)
Rmerge 0.111 (1.81) 0.148 (0.840)
Refinement
Protein atoms 5268 5210
Solvent atoms 566 H2O, 2 Ni
2+, 2 Cl−,
1 SO4
2−
412 H2O, 2 Ni
2+, 1 Cl−,
3 PO4
3−
Rwork 0.179 0.188
Rfree 0.216 0.240
R.m.s.d. bonds
(Å)
0.003 0.003
R . m . s . d .
angles (°)
0.76 0.69
Ramachandran
plot
F a v o u r e d
(%)
95.1 92.8
Outliers (%) 0 0
Fig. 1. Crystal structures of (A) fibromodulin and (B) chondro
disulphide bonds are shown as yellow sticks. The C-terminal ca
magenta. The fourN-linked glycans of fibromodulin are shown as
LRRs are labelled with roman numerals (see Fig. S1 for sequen
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number of cell surface receptors, such as the Toll-like
receptors involved in innate immunity [18], the platelet
vonWillebrand factor receptor, glycoprotein Ib [19,20],
and proteins involved in neural development [21,22].
The defining feature of these proteins is the presence
of multiple repeats of 20–30 amino acids in length and
starting with the consensus sequence LxxLxLxxNxL
(L can be substituted by I, V or other hydrophobic
residues). The folding principle of LRR proteins was
revealed by the crystal structure of ribonuclease
inhibitor [23]: the conserved leucine residues form the
hydrophobic core of a curved solenoid structure that is
characterised by an inner concave face composed of
parallel β-strands and an outer convex face composed
of variable structure. In proteins with long LRRs, such
as ribonuclease inhibitor, the outer face consists of
α-helices and the solenoid is highly curved; in proteins
with short LRRs, the helices are replaced by loops and
turns, which reduces the solenoid's curvature [16].
Interaction partners of LRR proteins frequently bind
to the concave face [16]. Indeed, several modelling
and mutational studies have implicated the concave
face of SLRPs in collagen binding [4,24–29]. The
crystal structure of the prototypical class I SLRP,
decorin, revealed a tight dimer in which most of the
concave face is occluded [30]. This finding led to a
controversy about the physiological state of decorin
and other SLRPs [31–33], which was only recently
resolved by the demonstration that decorinadherin. The LRRNTs are coloured blue in both proteins and
p of fibromodulin is in green, with the ear loop highlighted in
cyan sticks. The LRRCTof chondroadherin is in purple. The
ces).
Fig. 2. Histidines and aromatic residues on the concave faces of (A) fibromodulin and (B) chondroadherin. Histidines are
shown in orange, aromatic residues (Phe, Tyr, Trp) are shown in blue. The N- and C-termini are labelled.
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bind collagen through its concave face [26]. Even so,
further structural studies of theSLRP family are clearly
warranted. At the time of writing, the only crystal
structures available were those of two closely related
class I SLPRs, decorin [30] and biglycan [33]; a
chondroadherin structure was published while this
manuscript was in preparation [34]. Here, we report
the crystal structure of fibromodulin and a different
crystal form of chondroadherin, which reveal that these
SLRPs do not self-associate in the same manner
as decorin or biglycan. We also identify, using the
CollagenToolkits [35], a uniquecollagensequence that
binds with high affinity to chondroadherin and is distinct
from sequences that bind fibromodulin.
Results
Crystal structure of fibromodulin
The LRR region of fibromodulin is preceded by
~50 residues predicted to be unstructured and
including a number of sulphated tyrosines [36]. We
obtained crystals of a natively glycosylated human
fibromodulin construct in which ten N-terminal
tyrosines were mutated to serine to abolish
sulphation (N-terminally truncated fibromodulin
was not well expressed). The fibromodulin crystal
structure at 2.21 Å resolution (Table 1) is complete
except for the disordered N-terminal region. The
asymmetric unit of the crystals contains two
structurally very similar copies of fibromodulin
(r.m.s. deviation of 0.2 Å for 306 Cα atoms).
Human fibromodulin contains four potentialN-linked glycosylation sites at Asn127, Asn166,
Asn201, and Asn291. We observed electron
density for the innermost four sugar moieties at all
four sites, namely the two N-acetyl-glucosamines
of the chitobiose core, the branching mannose, and
a f u c o s e α 1 , 6 - l i n k e d t o t h e f i r s t
N-acetylglucosamine. Whether any of these gly-
cans is extended by keratan sulphate [37,38] could
not be determined from the electron density.
Fibromodulin adopts the curved solenoid structure
characteristic of all LRR proteins (Fig. 1A). The N-
terminal cap (LRRNT, 79-106) contains two conserved
disulphide bonds (Cys76-Cys82, Cys80-Cys92) and
seals the hydrophobic core of the LRR region. The cap
contributes one strand to the curved parallel β-sheet
that dominates the concave faceof fibromodulin. In the
decorin crystal structure, this strand was designated
as the first LRR [30]. In fibromodulin, its sequence
deviates substantially from the LRR consensus,
but we retain the decorin numbering for consistency.
The LRRNT of fibromodulin is followed by eleven
LRRs (II-XII) that contain the consensus sequence
LxxLxLxxNxL. The total length of the LRRs varies
between 20 and 27 residues (Fig. S1A). The LRRs in
fibromodulin follow a long-long-short pattern, as
previously described for decorin [30]. Residues 3–6
of each LRR contribute one β-strand to the concave
face of the curved solenoid; the convex face is made
up of loops and turns. LRR XI contains a protruding
loop that is characteristic of SLRP classes I, II or III
and has been termed the “ear” [30]. The ear spans
from the first conserved C-terminal cysteine (Cys334,
disulphide bonded to Cys367) to the β-strand of LRR
XII. The last five residues of fibromodulin form the 13th
strand of the concave β-sheet.
Fig. 3. Concave face interactions in SLRP crystal structures. For each structure, two orthogonal views are shown.
Decorin and biglycan form stable dimers in solution [26,32,33]. In contrast, fibromodulin and chondroadherin are
predominantly monomeric in solution (this work, Fig. 4) and the interactions shown are likely to be crystal lattice artefacts.
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In contrast to fibromodulin, chondroadherin does not
contain an N-terminal tyrosine sulphate-rich region orFig. 4. Oligomeric states of fibromodulin and chondroadherin
column at a concentration of 10 mg/ml and the molecular masse
peaks are truncated due to saturation of the signal. FMOD, fibroany N-linked glycans. We obtained crystals of human
chondroadherin and determined the structure at
2.17 Å resolution (Table 1). The structure is complete
except for the C-terminal 13 residues. The asymmetricin solution. The proteins were injected onto a size exlusion
s determined by multi-angle light scattering. The absorbance
modulin; CHAD, chondroadherin.
Fig. 5. Collagen binding by chondroadherin. (A) Binding of biotinylated chondroadherin to immobilised Collagen Toolkit
II peptides. Binding was detected with streptavidin-HRP and TMB substrate (absorbance at 450 nm). Error bars show
standard deviation from three technical replicates. (B) Dose-response curve of chondroadherin binding to peptide II-26
peptide interaction. (C) Inhibition of the chondroadherin-collagen II interaction by peptide II-26 peptide (solid line) or
peptide III-8 (negative control, dashed line). (D) Binding of peptide AB31 to chondroadherin (CHAD) in solution analysed
by size exclusion chromatography. AB31 and chondroadherin were mixed in a 2:1 molar ration and incubated for 15 min
before injection onto the Superdex 75 column. The sequences of peptides II-26 and AB31 are indicated on the right and the
sequence common to both is shaded.
110 Structural and functional analysis of fibromodulin and chondroadherinunit of the crystals contains two structurally similar
copies of chondroadherin (r.m.s. deviation of 0.7 Å for
327 Cα atoms).
Chondroadherin also adopts a curved solenoid
structure, but there are a number of differences with
respect to the fibromodulin structure described above
(Fig. 1B). Firstly, theLRRNTdomainof chondroadherin
more closely corresponds to the consensus structure
with two anti parallel β-strands [39], and its second
strand is part of a standard LRR motif (Fig. S1B).
Secondly, the LRRs II-XI of chondroadherin are more
uniform in length (24–25 residues), resulting in a
slightly higher curvature of the concave face (Fig. 1).
Thirdly, the ear and LRR XII of fibromodulin are
replaced by a C-terminal cap (LRRCT) in chondroad-
herin. The LRRCT is a common C-terminal motif ofmany LRR proteins that are not SLRPs, such as
glycoprotein Ibα [19,20], Nogo receptor [40,41], Slit [42]
and Toll-like receptors [43]. The LRRCT is charac-
terised by a 10-residue α-helix and two disulphide
bonds (Cys304-Cys326 and Cys306-Cys346 in
chondroadherin).
Comparison of our chondroadherin structure
(crystallised at pH 4.8) with the structure recently
published (crystallised at pH ~ 10) [34] reveals no
noteworthy differences in tertiary structure: the
average r.m.s. deviation of the eight pairwise
superpositions of crystallographically indepen-
dent chains is 0.94 ±0.31 Å (322 Cα atoms).
However, the chondroadherin monomers are
packed differently in the two crystal lattices (see
below).
Fig. 6. Alignment of chondroadherin binding and cross-linking sites in collagen fibres. Shown at the top is the staggered
arrangement of tropocollagen molecules within a collagen fibre, with D-periods labelled D1 to D4 (the red segment is D5).
The expanded view shows the vertical alignment of D1–D4. The chondroadherin-binding sequence from Toolkit peptide
II-26 is locatedmainly inD2, but extends intoD3 (sequences from the adjacentD-period are in italics). TheKGHRcross-linking
motif in D4 aligns exactly with the chondroadherin binding site in D2. The KGHR motif in D1 is axially displaced by ~40 nm
towards the N-terminus of the fibre.
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We noticed that untagged fibromodulin and chon-
droadherin showed substantial affinity for Ni2+ resin
and exploited this property for the purification of
chondroadherin. In the crystal lattices of both fibromo-
dulin and chondroadherin, neighbouringmolecules are
linkedbyheavy atomscoordinated bymultiple histidine
residues, most likely Zn2+ or Ni2+ (not shown). These
observations prompted us to examine the distribution
of histidines in fibromodulin and chondroadherin. We
found that histidines, as well as aromatic residues,
are markedly concentrated on the concave faces of
fibromodulin and chondroadherin (Fig. 2), explaining
their binding to Ni2+ affinity resin. Fibromodulin and
chondroadherin bothhaveprominent aromatic patches
in the N-terminal halves of their concave faces, which
are likely sites of protein-protein interactions. Indeed,
as described in the next paragraph, these patches
mediate important lattice interactions in the crystals.
Comparison of SLRP crystal structures
Previously, crystal structures of the core proteins
of two class I SLRPs were reported: decorin [30] and
biglycan [33]. Pairwise superpositions show thatTable 2. Pairwise sequence identities and structural
similarities of four SLRPs. The r.m.s. deviations were
calculated with the program PDBe Fold v2.59 [59] and the
number of matched Cα atoms is indicated in parentheses.
Fibromodulin Decorin Biglycan
Chondroadherin 26%
2.2 Å (267)
26%
1.7 Å (279)
27%
2.0 Å (277)
Fibromodulin 26%
2.1 Å (281)
23%
2.6 Å (269)
Decorin 58%
1.5 Å (301)decorin and biglycan more closely resemble each
other than either fibromodulin or chondroadherin
(Table 2). However, there is no straightforward
correlation between sequence identity and structural
similarity, as measured by the r.m.s. deviation of
global superpositions. Apart from chondroadherin
uniquely containing a LRRCT, the four SLRP struc-
tures differ subtly in the curvature of their β-sheets and
in the connecting loops on the convex outside of the
curved solenoid.
The decorin and biglycan structures revealed a
conserved mode of dimerisation, consistent with the
strong tendency of these proteins to dimerise in
solution [30,32,33]. The crystal packing of fibromodu-
lin and chondroadherin does not show the samemode
of association (Fig. 3). While there are contacts
between the concave faces in the fibromodulin and
chondroadherin crystals, the paired molecules are
arrangeddifferently, with the two solenoids crossing at
an angle rather than forming the elongated dimers of
decorin and biglycan. Notably, the packing of chon-
droadherin molecules in our crystal structure is
different from that seen in another chondroadherin
structure [34], suggesting that the concave face
interactions are not physiologically relevant (Fig. 3).
We used size exclusion chromatography with multi-
angle light scattering (SEC-MALS) to determine the
oligomeric states of fibromodulin and chondroadherin
in solution (Fig. 4). The experimentally determined
mass of fibromodulin was 56.7 kDa (calculated:
41.5 kDa + 4 N-linked glycans) and that of chon-
droadherin was 39.6 kDa (calculated: 38.6 kDa). In
comparison, using the same SEC-MALS setup, we
previously determined an experimental mass of
83.5 kDa for the glycosylated decorin core protein
(calculated: 36.2 kDa + 4 N-linked glycans) [26].
The results demonstrate that, unlike decorin, neither
fibromodulin nor chondroadherin forms a stable dimer
in solution. Given that the UV absorbance of the
eluting peaks was saturated in our SEC-MALS
112 Structural and functional analysis of fibromodulin and chondroadherinexperiment (Fig. 4), we estimate that the peak protein
concentration was at least 50 μM. Thus, if fibromodu-
lin or chondroadherin have any tendency to form
dimers, their dissociation constant would have to be
substantially higher than that of the decorin dimer,
which is 1.4 μM [26].
As noted previously [30,39], the interface residues
in the decorin and biglycan dimers are highly
conserved (79% identity). These residues, in partic-
ular those involved in hydrogen bonds or salt bridges,
are poorly conserved in fibromodulin (21%) and
chondroadherin (24%).Wealso note that the residues
involved in the dimeric crystal contacts of fibromodulin
and chondroadherin are not conserved between
these two proteins.
Identification of a unique chondroadherin binding
site in collagen
The Collagen Toolkits are a set of overlapping
triple-helical peptides, designed to allow the mapping
of collagen-binding proteins onto collagens II and
III with 9-residue resolution [35]. Here, Collagen
Toolkit II was used in solid-phase binding assays
to investigate binding sites for chondroadherin.
A single Toolkit peptide, II-26, supported chondroad-
herin binding; all other peptides showed only
basal levels of binding (Fig. 5A). No binding of
chondroadherin to Collagen Toolkit III was detected
(not shown). Dose-dependent binding of chondroad-
herin to II-26 reached half-maximum saturation
at ~3 μg/ml chondroadherin, corresponding to an
apparent dissociation constant of ~75 nM (Fig. 5B),
and II-26 inhibited the binding of chondroadherin
to immobilised collagen II (Fig. 5C). We prepared
a truncated version of II-26, AB31, for co-
crystallisation trials. AB31 formed a complex with
chondroadherin in solution (Fig. 5D), demonstrating
that the GAOGPSGFQGLOGPOGPO sequence
(O is hydroxyproline) shared by II-26 and AB31
provides a high-affinity binding site for chondroad-
herin. This sequence is located mainly within D-
period D2 but extends across the D2-D3 boundary
(Fig. 6). Further work is needed to identify exactly
those residues that interact with chondroadherin.
The purified chondroadherin-AB31 complex crystal-
lised readily at low pH, but unfortunately the
crystals invariably contained only chondroadherin
and not the peptide. We were unable to obtain
crystals at neutral pH, where the chondroadherin-
AB31 complex appears to be quite stable (Fig. 5D).Discussion
The fibromodulin and chondroadherin structures
reported here reinforce the notion that SLRPs are
versatile scaffolds for protein interactions. While theoverall fold of SLRPs is conserved and can be
predicted reliably from homology, their modes of
self-association vary and cannot be predicted.
Decorin and biglycan were found to form very similar
dimers that are quite stable in solution [30,33].
Fibromodulin and chondroadherin, in contrast, do
not dimerise stably in solution, and their crystal
packing shows a wide range of, presumably non-
physiological, concave face interactions (Fig. 3). A
recent study proposed that chondroadherin may form
physiological dimers, but this proposal was based
solely on an analysis of crystal lattice interactions and
computational docking [34]. Our SEC-MALS experi-
ment (Fig. 4) shows that chondroadherin dimerisation
in solution is, at best, veryweak.Wespeculate that the
frequent self-association of LRR-containing proteins
through their concave facesmay be driven by general
geometric and physico-chemical reasons: for curved
solenoid structures, the clasping of their concave
surfaces may be the easiest way of burying surface
areas that frequently contain exposed aromatic
residues.
Previous studies with bacterially expressed fibro-
modulin fragments identified LRRs 5-7 and 11
(VI-VIII and XII in the numbering scheme used here)
as important for collagen binding [4,25]. Thus, the
collagen binding site appears to be located in the
C-terminal half of fibromodulin, potentially leaving
the N-terminal half containing most of the surface-
exposed aromatic residues free to interact with
another partner. Lysyl oxidase has been shown to
bind to the very N-terminus of fibromodulin [9], which
is not ordered in our crystal structure.
The collagen-binding site on chondroadherin has
not been mapped. The C-terminal 14 residues of
chondroadherin, which are not resolved in our
structure, bind heparan sulphate [15]. Chondroad-
herin residues 307–318 have been identified as a
binding site for integrin α2β1 [44]. These positions
map to the α-helix in the C-terminal cap of chon-
droadherin. Glu316, the last residue of the α-helix,
appears to be critical for integrin binding and may
interact with the metal ion-dependent adhesion site of
the integrin α2 I domain [45,46].
A major finding of the present study is that
chondroadherin binds to a unique sequence motif
in collagen II, GAOGPSGFQGLOGPOGPO (six of
the nine triplets of primary sequence in Toolkit
peptide II-26), and not at all to collagen III. In this
respect, chondroadherin differs from fibromodulin,
which bound several Toolkit peptides from both
collagens II and III [9]. The chondroadherin-binding
motif has a GFx triplet in common with several other
collagen-binding proteins, but only one other protein,
OSCAR, has been mapped to peptide II-26 to
date [47]. Chondroadherin knockout mice present
with a widened epiphyseal growth plate, consistent
with impaired transition from cartilage to bone, which
may imply a role for chondroadherin in facilitating
113Structural and functional analysis of fibromodulin and chondroadherinthe osteoclastic resorption of calcified cartilage.
II-26 contains a 15-residue sequence that is sufficiently
conserved in both the α1 and α2 chains of collagen
I, but not in collagen III, to suggest that this same
site in collagen I supports the reported binding of
chondroadherin to collagen I [11]. It is also of
interest that, in the alignment of collagen D-periods
(Fig. 6), the II-26 sequence is located mainly within
the C-terminal end of D2 where its GFQ triplet
aligns perfectly with the collagen cross-linking site,
KGHR, in D4 that is the target for condensation
with oxidised lysine in nearby N-collagen telopeptides.
This suggests a potential role for chondroadherin
in collagen fibril assembly and cross-linking, as
previously suggested [13], although a later study
reported normal organisation of bone collagen in
chondroadherin knockout mice but alteredmechanical
properties and trabecular bone organisation [11].
We have previously proposed a role for fibromodulin
in collagen cross-linking, which itself binds to
KGHR-containing sites in Collagen Toolkits II and III
[9].Materials and methods
Expression vectors
The coding sequence for human fibromodulin with
ten tyrosine residues in the N-terminal region mutated
to serine (Y38S, Y39S, Y42S, Y45S, Y47S, Y50S,
Y53S, Y55S, Y63S, Y65S) was synthesised by
Genscript and cloned into a modified pCEP-Pu vector
containing the BM-40 signal peptide sequence [48].
The fibromodulin construct comprises residues 19–
376 of UniProt Q06828 and contains a tobacco etch
virus (TEV) protease-cleavable His-tag at the
N-terminus [49]; after secretion and TEV protease
treatment, a vector-derived GALA sequence remains
present at the N-terminus. The coding sequence
for human chondroadherin was amplified from cDNA
and cloned into the original pCEP-Pu vector contain-
ing the BM-40 signal peptide sequence [48]. The
construct comprises residues 23–359 of Uniprot
O15335 and is untagged; after secretion, a vector-
derived APLA sequence remains present at the
N-terminus. All expression vectors were verified by
DNA sequencing.
Protein expression and purification
Human embryonic kidney HEK293 c18 cells
(ATCC) were used for protein production. The cells
were grown at 37 °C with 5% CO2 in Dulbecco's
modifiedEaglemediumF12 (ThermoFisherScientific)
containing 10% fetal bovine serum, 2 mM glutamine,
10 U/ml penicillin, 100 μg/ml streptomycin, and
250 μg/ml geneticin. Cells were transfected with theexpression vectors usingFugene (RocheDiagnostics)
and selected with 1 μg/ml puromycin (Sigma). Trans-
fected cells were grown to confluence in HYPER-
Flasks (Corning), washed twice with PBS, and
incubated with serum-free medium for up to 5 weeks
with one medium exchange per week.
For purification of His-tagged fibromodulin, the
filtered serum-free cell culture supernatant was adjust-
ed to a final concentration of 20 mM Na-HEPES
(pH 7.5) and loaded onto a 5-ml HisTrap Excel column
(GE Healthcare) using an Äkta Purifier (GE Health-
care). The column was washed with buffer A (20 mM
HEPES pH 7.5, 150 mM NaCl, 2 mM CaCl2) and the
protein was eluted with 500 mM imidazole in buffer A.
To remove the His-tag, fractions containing protein
were incubated overnight with recombinant His-tagged
TEV protease (made in E. coli using an expression
vector kindly provided by Stephen Curry) while dialys-
ing against buffer A. The reaction mixture was passed
over a5-mlHisTrapExcel column, and the flow-through
containing the untagged fibromodulin protein was
collected. After concentration using a Vivaspin centrif-
ugal device (Sartorius), the fibromodulin protein was
further purified by size exclusion chromatography on a
Superdex 75 10/300GL column (GEHealthcare) using
buffer A as the running buffer. The purified protein ran
as a single broad band of ~55 kDa on reducing
SDS-PAGE (calculated: 41.5 kDa + 4 N-linked
glycans).
The natural affinity of chondroadherin for Ni2+
affinity resin was used to purify the untagged protein.
The filtered serum-free cell culture supernatant was
adjusted to a final concentration of 20 mMNa-HEPES
(pH 7.5) and loaded onto a 5-ml HisTrap Excel
column using an Äkta Purifier. Elution was performed
with an imidazole gradient in buffer A. The chon-
droadherin protein was further purified by size
exclusion chromatography as described for fibromo-
dulin. Chondroadherin and the collagen-like peptide
AB31 were mixed in a 1:2 molar ratio and incubated
f o r 1 5 m i n a t r o om t empe r a t u r e . The
chondroadherin-AB31 complex was purified by size
exclusion chromatography in buffer A.
Peptide synthesis
Toolkit peptides, as C-terminal amides, were
synthesised on TentaGel R-Ram resin using Fmoc
chemistry in a CEM Liberty microwave-assisted
synthesiser as described [9]. Toolkit peptides have
the form: GPC-[GPP]5-[27aa]-[GPP]5-GPC. A neutral
control peptide, GPC-[GPP]10-GPC, called GPP10,
consists of the flanking regions alone. In all cases,
fractions containing homogeneous product were
identified by analytical HPLC on an ACEphenyl300
(5 mm) column, characterised by MALDI-TOF mass
spectrometry, pooled and freeze-dried. All have been
shown, using polarimetry, to adopt triple-helical
conformation [50].
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Crystal screening was done at room temperature
by the sitting-drop vapor diffusion method using
96-well plates (Greiner) and a range of commercial
screens. A Mosquito nanolitre robot (TTP Labtech)
was used to set up 200 nl sitting drops.
Crystals of untagged fibromodulin were obtained
from a 10 mg/ml protein solution after one month at
condition C6 of the Wizard Classic 3 screen (Rigaku)
and at condition G5 of the Index screen (Hampton
Research), but these crystals did not diffract to high
resolution when cryoprotected with 30% glycerol. A
range of crystallisation conditions and cryoprotectants
were screened. The best results were obtained by
growing the crystals at 26% (w/v) PEG 3350, 200 mM
lithium sulphate monohydrate, 100 mM Tris-HCl
(pH 8.5) and using an additional 15% PEG 3350 as
cryoprotectant.
The chondroadherin-AB31 complex crystallised
under a wide range of conditions at acidic pH, but the
crystals were later found to contain only chondroad-
herin. When tested, chondroadherin alone crystallised
under the sameconditions. Thebest crystals grew from
a 10 mg/ml protein solution in 20 mM Tris-HCl pH 7.5,
150 mMNaCl, 2 mMCaCl2 using 200 mMmonobasic
potassium phosphate (pH 4.8), 20% (w/v) polyethyl-
eneglycol 3350asprecipitant. Crystalswere harvested
in reservoir solution supplemented with 20% ethylene
glycol and flash-frozen in liquid nitrogen.
Crystal structure determination
Diffraction data were collected at 100 K at beamlines
I04-1 and I24 of the Diamond Light Source, Oxfordshire,
UK. The data were processed using XDS [51] and
programs of the CCP4 suite [52] as implemented in the
XIA2 pipeline [53]. CC1/2 was used to determine the
resolution limit [54]. Both fibromodulin and chondroad-
herin crystals belong to space group C2 with two
molecules in the asymmetric unit. The phases were
determinedbymolecular replacement usingPHASERas
implemented in the PHENIX suite [55]. The search
models were derived from the crystal structure of decorin
(PDB 1XKU) [30]. Automatic and manual building was
done using AutoBuild in PHENIX and Coot [56],
respectively. Refinement was done using PHENIX.
Figures were generated using PyMOL (www.pymol.org).
Size exclusion chromatography with multi-angle
light scattering
Fibromodulin and chondroadherin samples at a
concentration of 10 mg/ml were injected onto a Super-
dex 75 10/30 column (GE Healthcare) connected to a
1260 InfinityHPLC (Agilent Technologies). The running
bufferwas 150 mMNaCl, 20 mMHEPES (pH 7.5) and
the flow rate was 0.1 ml/min. Light scattering and
refractive index changes were monitored using in-lineWyatt Mini Dawn and Optilab T-rEX detectors (Wyatt
Technology Corp). The data were analysed with the
Wyatt ASTRA V software. Each N-linked glycosylation
site was assumed to add 2 kDa of molecular mass.
The extinction coefficients for fibromodulin and
chondroadherin were calculated as 32,930 and
40,715 M−1 cm−1, respectively.
Collagen binding assays
Recombinant purified chondroadherin was bio-
tinylated using biotin EZ-link reagent (ThermoFisher)
and dialysed into TBS to remove excess biotinylation
reagent. Collagen peptides from Toolkit II and III
[57,58] were coated on a 96-well plate at 10 μg/ml in
20 mM acetic acid overnight at 4 °C. BSA and
(GPP)10 triple-helical peptides were used as negative
controls. The following incubations were conducted at
room temperature. Plateswere rinsed three timeswith
TBS and blocked for 1 h with 5% BSA in TBS. After
rinsing with TBS, plates were incubated with biotinyl-
ated chondroadherin at 10 μg/ml in TBST (TBS with
0.1% Tween-20) with 0.1% BSA for 1 h. Plates
were washed three times with TBST, and incubated
with streptavidin-HRP (Millipore) diluted 1:20,000
in TBST with 0.1% BSA for 1 h. Plates were washed
five times with TBST, and the binding was detected
with TMB substrate (ThermoFisher) and stopped with
2 M sulphuric acid. The absorbance was read at
450 nm.
For chondroadherin-collagen II binding assays the
plates were coated with acid-solubilized collagen II
(Sigma) diluted to 10 μg/ml in 20 mM acetic acid.
The rest of the assay was carried out as above, but
chondroadherin was diluted 1:2 in 15 steps starting
from 10 μg/ml. Similar procedures were used in
chondroadherin-collagen II inhibition assays, in
which Toolkit peptides II-26 or III-8 were used as
inhibitors at concentrations of 50, 100, 200, 400 μg/ml
pre-incubated for 1 h with 10 μg/ml biotinylated
chondroadherin.
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